Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions

Area of Science:

• Hematology
• Oncology
• Clinical Pharmacology

Background:

• Novel therapies have significantly improved initial treatment responses in multiple myeloma.
• Despite advances, disease relapse remains a major challenge, necessitating different therapeutic strategies.
• The relapsed setting presents unique challenges and opportunities for novel therapeutic agents.

Purpose of the Study:

• To review clinical trial evidence for novel agents in relapsed multiple myeloma.
• To examine the efficacy of triplet therapies, particularly adding novel agents to established backbones.
• To provide a basis for clinical decision-making in the evolving landscape of relapsed multiple myeloma treatment.

Main Methods:

• Review of clinical trial data for novel agents in multiple myeloma.
• Focus on triplet therapy combinations, including proteasome inhibitors (carfilzomib, ixazomib) and monoclonal antibodies (elotuzumab, daratumumab).
• Consideration of data for adding agents (panobinostat, elotuzumab, daratumumab) to bortezomib and dexamethasone backbone.

Main Results:

• Data support adding carfilzomib, ixazomib, elotuzumab, or daratumumab to lenalidomide and dexamethasone.
• Evidence is less developed for adding panobinostat, elotuzumab, or daratumumab to bortezomib and dexamethasone.
• Lack of head-to-head data necessitates careful interpretation of available regimen comparisons.

Conclusions:

• Novel agents show promise in triplet regimens for relapsed multiple myeloma.
• Further research and head-to-head trials are needed to optimize treatment selection.
• This review consolidates current data to aid clinical decision-making in a rapidly advancing field.